The 7-OH Comment Window Has Closed. It Was Never The Thing That Decides The Ban.

The federal comment docket on the 7-hydroxymitragynine threshold closed at the end of the day on September 10. As of this morning, regulations.gov lists the docket as no longer open for comment and not accepting late submissions. The Drug Enforcement Administration's temporary scheduling order on 7-OH, the action the docket was widely described as a last chance to stop, has not issued. Nothing matching the compound appears in today's Federal Register or on public inspection for tomorrow's.

In the weeks before the deadline, this publication saw the docket presented in industry and advocacy channels as the vote that decides whether 7-OH is banned. Now that it has closed, it is worth setting out plainly what closing changes, what it does not, and what is actually pending.

Two Agencies, Two Tracks, One Compound

Two different parts of the federal government have been working on 7-OH at the same time, under different authorities, on different clocks. The confusion was structural, and it was understandable.

The Drug Enforcement Administration holds the scheduling authority. On July 6 it published a notice of intent to place 7-hydroxymitragynine above a specified threshold into Schedule I on a temporary basis under the Controlled Substances Act. That notice stated the order would not publish before August 5. The statutory minimum has long since elapsed. The final order can publish on any day, without further warning, and would take effect on publication.

The Department of Health and Human Services, through the Office of the Assistant Secretary for Health, opened a separate public docket the same day: a request for information on the proposed threshold itself. That docket, HHS-OASH-2026-0232, is the one that closed September 10. Its original window ended July 31. On August 26, OASH extended it by fifteen days, stating in the extension notice that it was acting "in response to a request for an extension to allow interested persons additional time to provide comments and input."

The two tracks are related but not sequenced. Nothing in either document states that the DEA order waits on the HHS docket, and this publication has found no basis in the public record for that assumption. The docket closing does not create a date on which the order issues. The order issuing would not, by itself, have closed the docket.

What Closing Actually Means

The extension notice describes what happens to the submissions in one sentence: "Public comments submitted to this docket will be provided by the Secretary for Health and Human Services for consideration by the Attorney General." That is the mechanism. The Attorney General, acting through the DEA, holds the scheduling decision. HHS collected input on the threshold and passes it along. There is no announced date by which that consideration concludes and no public step between the docket closing and an order publishing.

What the docket asked was narrower than "should 7-OH be banned." The DEA's proposal does not reach 7-OH at any concentration. It reaches material above a line: botanical material of Mitragyna speciosa containing more than 0.050 percent 7-hydroxymitragynine on a dry weight basis, and processed articles containing more than 1.00 milligram of 7-OH. The HHS docket solicited input on that threshold, on whether the number sits in the right place and what evidence bears on it.

The line is the mechanism by which the proposal separates leaf from concentrated and synthesized material. The Food and Drug Administration states on its own 7-OH page that the federal measures "are intended to target concentrated and synthetic 7-OH products and are not intended to apply to natural kratom leaf containing only naturally occurring trace levels of 7-OH." Whether the order as issued keeps that threshold, moves it, or changes its scope is the question the docket fed into. It is not one the docket answered.

What Is In The Record

As of September 11, regulations.gov lists 30,110 posted comments on docket HHS-OASH-2026-0232. That figure counts comments the agency has processed and posted, and agencies typically continue posting submissions received near a deadline for some time afterward, so the final number may be higher. Coverage in trade and advocacy outlets during the first round cited figures above 32,000. This publication reports the regulations.gov count because it is the one that can be checked.

The volume establishes that the threshold question was heavily commented on. It does not establish what the comments say, and it does not establish what weight they carry. An agency is obliged to consider material submitted to a docket it opened. It is not obliged to agree, to respond individually, or to change course because of submission volume. The 2016 attempt to schedule mitragynine and 7-hydroxymitragynine, the only prior federal try at kratom's alkaloids, ended when the DEA withdrew its notice of intent that October after receiving what it described as "numerous comments from members of the public." That is a fact about 2016. Nothing in the current record indicates the same outcome, and this publication does not predict one.

What Has Not Waited

The pending order is not the only federal action on the table, and it is not the only action at all. The DEA's separate order placing mitragynine pseudoindoxyl, MGM-15 and MGM-16 into Schedule I published and took effect on August 26, the same morning as the HHS extension notice. That order carries no threshold and was unaffected by the docket at every stage. This publication has covered what it reaches and what it does not.

States have also stopped waiting. Massachusetts placed all forms of kratom into its state Schedule I by emergency order, with no threshold and no carve-out for leaf, as this publication reported in August. State law on kratom now varies considerably and is worth checking locally regardless of anything the DEA does or does not publish.

What This Publication Is Not Saying

This report took no position on whether anyone should have commented, and takes none now on what the comments should produce. The Kratom Council does not run advocacy campaigns and did not organize one around this docket. Its interest was, and is, that readers of a kratom news publication should know what a federal docket is for and should not be told a procedural window is a referendum.

Nor does anything here predict where the threshold lands, or when. The proposal is a proposal. The order has not issued. The docket has closed either way.

The Dates That Matter Now

Closed as of September 10, 2026: the HHS comment docket on the 7-OH threshold. Pending, with no announced date: the DEA's temporary scheduling order on 7-OH above the threshold, which can publish on any day and takes effect on publication, for two years with a possible one-year extension. In force since August 26 and unaffected by either: the Schedule I placement of mitragynine pseudoindoxyl, MGM-15 and MGM-16. Unchanged by any current federal action: natural kratom leaf, which remains governed by state law.

The Kratom Council checks the Federal Register each morning and will report the order the day it publishes.